The second nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan, 2012-2013

Ryoichi Hamasuna; Mitsuru Yasuda; Kiyohito Ishikawa; Shinya Uehara; Hiroshi Hayami; Satoshi Takahashi; Tetsuro Matsumoto; Shingo Yamamoto; Shinichi Minamitani; Akira Watanabe; Satoshi Iwata; Mitsuo Kaku; Junichi Kadota; Keisuke Sunakawa; Junko Sato; Hideaki Hanaki; Taiji Tsukamoto; Hiroshi Kiyota; Shin Egawa; Kazushi Tanaka; Soichi Arakawa; Masato Fujisawa; Hiromi Kumon; Kanao Kobayashi; Akio Matsubara; Seiji Naito; Kentaro Kuroiwa; Hideo Hirayama; Harunori Narita; Takahide Hosobe; Shin Ito; Kenji Ito; Shuichi Kawai; Masayasu Ito; Hirofumi Chokyu; Masaru Matsumura; Masaru Yoshioka; Satoshi Uno; Koichi Monden; Kazuo Takayama; Shinichi Kaji; Motoshi Kawahara; Toru Sumii; Hitoshi Kadena; Takamasa Yamaguchi; Shinichi Maeda; Shohei Nishi; Hirofumi Nishimura; Takeshi Shirane; Mutsumasa Yoh; Kikuo Akiyama; Toshio Imai; Motonori Kano

doi:10.1016/j.jiac.2015.01.010

The second nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan, 2012-2013

J Infect Chemother. 2015 May;21(5):340-5. doi: 10.1016/j.jiac.2015.01.010. Epub 2015 Jan 31.

Authors

Ryoichi Hamasuna¹, Mitsuru Yasuda², Kiyohito Ishikawa³, Shinya Uehara⁴, Hiroshi Hayami⁵, Satoshi Takahashi⁶, Tetsuro Matsumoto⁷, Shingo Yamamoto⁸, Shinichi Minamitani⁹, Akira Watanabe¹⁰, Satoshi Iwata¹⁰, Mitsuo Kaku¹⁰, Junichi Kadota¹⁰, Keisuke Sunakawa¹⁰, Junko Sato¹⁰, Hideaki Hanaki¹¹, Taiji Tsukamoto¹², Hiroshi Kiyota¹³, Shin Egawa¹⁴, Kazushi Tanaka¹⁵, Soichi Arakawa¹⁵, Masato Fujisawa¹⁵, Hiromi Kumon¹⁶, Kanao Kobayashi¹⁷, Akio Matsubara¹⁷, Seiji Naito¹⁸, Kentaro Kuroiwa¹⁸, Hideo Hirayama¹⁹, Harunori Narita²⁰, Takahide Hosobe²¹, Shin Ito²², Kenji Ito²³, Shuichi Kawai²⁴, Masayasu Ito²⁵, Hirofumi Chokyu²⁶, Masaru Matsumura²⁷, Masaru Yoshioka²⁸, Satoshi Uno²⁹, Koichi Monden³⁰, Kazuo Takayama³¹, Shinichi Kaji³², Motoshi Kawahara³³, Toru Sumii³⁴, Hitoshi Kadena³⁵, Takamasa Yamaguchi³⁶, Shinichi Maeda³⁷, Shohei Nishi³⁸, Hirofumi Nishimura³⁹, Takeshi Shirane⁴⁰, Mutsumasa Yoh⁴¹, Kikuo Akiyama⁴², Toshio Imai⁴³, Motonori Kano⁴⁴

Affiliations

¹ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan. Electronic address: hamaryo@med.uoeh-u.ac.jp.
² The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Gifu University Hospital, Gifu, Japan.
³ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, School of Medicine, Fujita Health University, Toyoake, Japan.
⁴ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
⁵ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Blood Purification Center, Kagoshima University Hospital, Kagoshima, Japan.
⁶ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
⁷ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
⁸ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Hyogo College of Medicine, Nishinomiya, Japan.
⁹ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
¹⁰ The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
¹¹ Research Center for Anti-infectious Drugs, Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan.
¹² Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
¹³ Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan.
¹⁴ Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
¹⁵ Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
¹⁶ Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
¹⁷ Department of Urology, Institute of Biomedical & Health Sciences Hiroshima University, Hiroshima, Japan.
¹⁸ Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹⁹ Hirayama Urology Clinic, Kumamoto, Japan.
²⁰ Narita Clinic, Nagoya, Japan.
²¹ Hosobe Clinic, Tokyo, Japan.
²² iClinic, Sendai, Japan.
²³ Ito Urology Clinic, Kitakyushu, Japan.
²⁴ Kawai Urology Clinic, Kitakyushu, Japan.
²⁵ Gifu Urological Clinic, Gifu, Japan.
²⁶ Chokyu Tenma Clinic, Himeji, Japan.
²⁷ Matsumura Urology Clinic, Kato, Japan.
²⁸ Yoshioka Urology Clinic, Nishinomiya, Japan.
²⁹ Hirajima Clinic, Okayama, Japan.
³⁰ Araki Urological Clinic, Kurashiki, Japan.
³¹ Department of Urology, Takayama Hospital, Chikushino, Japan.
³² Kaji Clinic, Fukuoka, Japan.
³³ Kawahara Urology Clinic, Kagoshima, Japan.
³⁴ Sumii Clinic, Hiroshima, Japan.
³⁵ Kadena Urological Clinic, Hiroshima, Japan.
³⁶ Yamaguchi Dermatology and Urology Clinic, Munakata, Japan.
³⁷ Department of Urology, Toyota Memorial Hospital, Toyota, Japan.
³⁸ Nishi Urology and Dermatology Clinic, Kitakyushu, Japan.
³⁹ Nishimura Urology Clinic, Kitakyushu, Japan.
⁴⁰ Shirane Urology Clinic, Aki-gun, Japan.
⁴¹ Yoh Urology and Dermatology Clinic, Inazawa, Japan.
⁴² Akiyama Urology Clinic, Nishinomiya, Japan.
⁴³ Imai Urology Clinic, Akashi, Japan.
⁴⁴ Department of Urology, Kano Hospital, Kasuya-gun, Japan.

PMID: 25727286
DOI: 10.1016/j.jiac.2015.01.010

Abstract

Worldwide, the most important concern in the treatment of sexually transmitted infections is the increase in antimicrobial resistant Neisseria gonorrhoeae strains including resistance to cephalosporins, penicillins, fluoroquinolones or macrolides. To investigate the trends of antimicrobial susceptibility among N. gonorrhoeae strains isolated from male patients with urethritis, a Japanese surveillance committee conducted the second nationwide surveillance study. Urethral discharge was collected from male patients with urethritis at 26 medical facilities from March 2012 to January 2013. Of the 151 specimens, 103 N. gonorrhoeae strains were tested for susceptibility to 20 antimicrobial agents. None of the strains was resistant to ceftriaxone, but the minimum inhibitory concentration (MIC) 90% of ceftriaxone increased to 0.125 μg/ml, and 11 (10.7%) strains were considered less susceptible with an MIC of 0.125 μg/ml. There were 11 strains resistant to cefixime, and the MICs of these strains were 0.5 μg/ml. The distributions of the MICs of fluoroquinolones, such as ciprofloxacin, levofloxacin and tosufloxacin, were bimodal. Sitafloxacin, a fluoroquinolone, showed strong activity against all strains, including strains resistant to other three fluoroquinolones, such as ciprofloxacin, levofloxacin and tosufloxacin. The azithromycin MICs in 2 strains were 1 μg/ml.

Keywords: 2012; 2013; Antimicrobial susceptibilities; Japan; Nationwide surveillance; Neisseria gonorrhoeae.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Anti-Bacterial Agents / pharmacology*
Azithromycin / pharmacology
Cefixime / pharmacology
Ceftriaxone / pharmacology
Drug Resistance, Bacterial*
Fluoroquinolones / pharmacology
Humans
Japan
Male
Microbial Sensitivity Tests
Middle Aged
Neisseria gonorrhoeae / drug effects*
Penicillins / pharmacology
Population Surveillance*
Urethritis / microbiology*
Young Adult

Substances

Anti-Bacterial Agents
Fluoroquinolones
Penicillins
Ceftriaxone
Azithromycin
Cefixime